Charles River Laboratories International (MIL:1CRL) Cyclically Adjusted Revenue per Share: €0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1CRL Charles River Laboratories International Inc MIL:1CRL
69 GF Score
Price €143.90
GF Value €121.93
! 8 Warning Signs
View Full Analysis

What is Charles River Laboratories International Cyclically Adjusted Revenue per Share?

Charles River Laboratories International MIL:1CRL 69 Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus rates MIL:1CRL with a GF Score™ of 69/100 and a GF Value™ of €121.93. The stock has 8 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Charles River Laboratories International's adjusted revenue per share for the three months ended in Mar. 2026 was €17.503. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.00 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Charles River Laboratories International's average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Charles River Laboratories International was 16.00% per year. The lowest was 6.30% per year. And the median was 10.20% per year.

As of today (2026-07-17), Charles River Laboratories International's current stock price is €143.90. Charles River Laboratories International's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.00. Charles River Laboratories International's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Charles River Laboratories International was 11.01. The lowest was 1.49. And the median was 3.99.


Charles River Laboratories International  (MIL:1CRL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Charles River Laboratories International was 11.01. The lowest was 1.49. And the median was 3.99.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Charles River Laboratories International Cyclically Adjusted Revenue per Share Related Terms


Charles River Laboratories International Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International Cyclically Adjusted Revenue per Share Chart

Charles River Laboratories International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Charles River Laboratories International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MIL:1CRL vs RVTY, QGEN, ICLR: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Charles River Laboratories International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Charles River Laboratories International Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Charles River Laboratories International's Cyclically Adjusted PS Ratio falls into.


MIL:1CRL
69GF Score
Charles River Laboratories International Inc MIL:1CRL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Charles River Laboratories International Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Charles River Laboratories International's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=17.503/330.2130*330.2130
=17.503

Current CPI (Mar. 2026) = 330.2130.

Charles River Laboratories International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 8.062 241.018 11.046
201609 7.897 241.428 10.801
201612 9.158 241.432 12.526
201703 8.608 243.801 11.659
201706 8.637 244.955 11.643
201709 8.049 246.819 10.769
201712 8.262 246.524 11.067
201803 8.205 249.554 10.857
201806 10.216 251.989 13.387
201809 10.169 252.439 13.302
201812 10.853 251.233 14.265
201903 10.817 254.202 14.051
201906 11.718 256.143 15.107
201909 12.200 256.759 15.690
201912 12.468 256.974 16.021
202003 12.806 258.115 16.383
202006 12.063 257.797 15.452
202009 12.446 260.280 15.790
202012 12.667 260.474 16.058
202103 13.561 264.877 16.906
202106 14.788 271.696 17.973
202109 14.771 274.310 17.781
202112 15.517 278.802 18.378
202203 16.168 287.504 18.570
202206 17.951 296.311 20.005
202209 19.481 296.808 21.674
202212 20.220 296.797 22.497
202303 18.695 301.836 20.453
202306 19.009 305.109 20.573
202309 18.640 307.789 19.998
202312 18.107 306.746 19.492
202403 17.951 312.332 18.979
202406 18.386 314.175 19.325
202409 17.638 315.301 18.472
202412 18.637 315.605 19.500
202503 17.902 319.799 18.485
202506 18.145 322.561 18.575
202509 17.322 324.800 17.611
202512 17.252 324.054 17.580
202603 17.503 330.213 17.503

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.00 mean?
Charles River Laboratories International (MIL:1CRL) has a Cyclically Adjusted Revenue per Share of €0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Charles River Laboratories International and its competitors.
Is Charles River Laboratories International's Cyclically Adjusted Revenue per Share too high?
Charles River Laboratories International's current Cyclically Adjusted Revenue per Share is €0.00. Overall, Charles River Laboratories International has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Cyclically Adjusted Revenue per Share compare to RVTY and QGEN?
Charles River Laboratories International's Cyclically Adjusted Revenue per Share of €0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current Cyclically Adjusted Revenue per Share is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Charles River Laboratories International (MIL:1CRL) has a current Cyclically Adjusted Revenue per Share of €0.00. The stock's GF Value™ is €121.93, compared to a current price of €143.90 — trading 18% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.00. Charles River Laboratories International's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Charles River Laboratories International (MIL:1CRL), the current Cyclically Adjusted Revenue per Share is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (MIL:1CRL) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of €143.90 is trading 18% above its estimated GF Value™ of €121.93.

Key valuation signals for MIL:1CRL:

  • Cyclically Adjusted Revenue per Share: €0.00
  • GF Value™: €121.93 vs. price of €143.90 (18% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the MIL:1CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Charles River Laboratories International Business Description

Other Exchanges CRL:USARV6:Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
69GF Score

Get the complete analysis for MIL:1CRL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.90
Price
€121.93
GF Value